Navigation Links
Onyx Pharmaceuticals Reports Second Quarter 2011 Financial Results
Date:8/3/2011

net (as recorded by Bayer)

$ 245,665$ 236,122$ 481,132$ 450,483Nexavar revenue subject to profit sharing (as recorded by Bayer)

$ 206,600$ 202,979$ 399,770$ 388,846Combined cost of goods sold, distribution, selling, general and administrative expenses

89,53083,022163,540158,720Combined collaboration commercial profit

$ 117,070$ 119,957$ 236,230$ 230,126Onyx's share of collaboration commercial profit

$   58,535$   59,978$ 118,115$ 115,063Reimbursement of Onyx's shared marketing expenses

6,6876,47511,29112,299Royalty revenue

2,7342,3205,6954,314Revenue from collaboration agreement

$   67,956$   68,773$ 135,101$ 131,676ONYX PHARMACEUTICALS, INC.RECONCILIATION OF GAAP TO NON-GAAP NET INCOME (LOSS)(In thousands, except per share amounts)(unaudited)Three Months EndedSix Months EndedJune 30, June 30, 2011201020112010GAAP net (loss)

$(54,543) $(97,182) $(103,703) $(109,227)Non-GAAP adjustments:Contingent consideration5,755 92,037 7,250 95,485 Employee stock-based compensation8,344 5,776 3,699 ,718 Imputed interest related to the convertible senior notes due 20162,509 2,222 4,944 4,379 Advance funding to S*BIO- - 2,666 - Impairment of equity investment in S*BIO- - 3,000 - Lease termination exit costs,727 - ,727 - Non-GAAP net (loss) / income (5) $(27,208) $
2,853 $  (41,417) $
,355 Computation of non-GAAP diluted net (loss) / incomeNon-GAAP net (loss) / income (5) $(27,208) $
2,853 $  (41,417) $
,355 Add:Interest and issuance costs related to dilutive convertible senior notes (6)-   -   -   -   Non-GAAP net (loss) / income - diluted (5) $(27,208) $
2,853 $  (41,417) $
,355 Computation of non-GAAP diluted sharesBasic shares3,415 2,627 3,212 2,491 Dilutive effect of convertible senior notes (6)- 73 - 222 Non-GAAP diluted shares (5)3,415 2,800 3,212 2,713 Non-GAAP net (loss) / income per share (5) $
(0.43) $
.
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Access Pharmaceuticals Adds Blue Cross Blue Shield of Hawaii, SummaCare and AvMed to MuGard Payer List
2. Lyophilisation for Pharmaceuticals: Technology and Services Market 2011-2021 - What are the Revenue Prospects?
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of August 2011
4. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
5. Pacira Pharmaceuticals, Inc. Announces Data Presentations at the 38th Annual Meeting & Exposition of the Controlled Release Society
6. MAP Pharmaceuticals Announces FDA Acceptance for Filing of NDA for LEVADEX®
7. FDA Grants Orphan Drug Status to Merrimack Pharmaceuticals MM-398, a Nanotherapeutic Encapsulation of Irinotecan, for the Treatment of Pancreatic Cancer
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Tuesday, August 9
9. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
10. Questcor Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 11, 2011
11. Cadence Pharmaceuticals Reaffirms FDA-Approved Dosing Recommendations for OFIRMEV® (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Burzynski Research Institute, Inc. (BRI) announced today that the ... company permission to conduct an open-label study of Antineoplastons ... age with a diffuse intrinsic brainstem glioma (DIPG). Study ... groups based on their age and whether or not ... study endpoint is a decrease in the size of ...
(Date:10/22/2014)...  Rescheduling of hydrocodone combination products (HCPs) will ... according to a new primary market research study ... research and consultation exclusively in the area of ... In August, the DEA ... from Schedule III to Schedule II status. This ...
(Date:10/22/2014)... BASKING RIDGE, N.J. , Oct. 22, 2014 ... (RMANJ), a world-renowned leader in the field ... more rapid approach to embryonic screening. The research ... American Society for Reproductive Medicine (ASRM) meeting in ... chromosome screening (CCS) and single gene defect (SGD) ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3
... 26, 2012  Richard Wolf Medical Instruments Corporation celebrates ... minimally invasive solutions that spare patients the costs ... (Logo:  http://photos.prnewswire.com/prnh/20120426/CG95191LOGO ) ... allowing doctors to visualize and access elusive sites ...
... April 26, 2012 - The Consumer Healthcare Products ... for signing into law House Bill 363, legislation ... implementing a drug offender registry, stricter penalties for ... stop-sale technology.  HB 363 and its companion legislation ...
Cached Medicine Technology:Richard Wolf Medical Instruments Corporation: 40 Years of Innovation 2
(Date:10/25/2014)... -- Arriving home safe and sound is one of the ... sure that costumes and goody bags have reflective strips that ... medicine doctor at Meadowlands Hospital Medical Center in Secaucus, N.J. ... should be flame-resistant, Davis said. He offers these others ... it on a small area of skin first to ensure ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... York, New York (PRWEB) October 25, 2014 ... transvaginal mesh lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed ... litigation underway in U.S. District Court, Southern District ... for Summary Judgment on Punitive Damages in a ... plaintiffs. In a ruling issued on October 21st, ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 (HealthDay ... herpes simplex -- might increase the risk of Alzheimer,s disease, ... a carrier of certain antibodies to the virus can double ... "The identification of a treatable cause [herpes simplex] of the ... Dr. Hugo Lovheim, an associate professor in the department of ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Tips for Safe Trick-or-Treating 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... , , , , ... on senior living communities, 43-year-old Steve Gurney, the founder and publisher ... a temporary resident of The Residences of Thomas Circle, a downtown ... on his blog www.everyoneisaging.com. , , During the ...
... , , WASHINGTON, Aug. 11 ... ZOOM-100DC brain electrical activity data collection system, has been cleared ... section 510(k) of the FD&C Act. The ZOOM-100DC is an ... and displaying EEG waveforms and providing conventional EEG measures displayed ...
... , , WILMINGTON, Mass., ... dermatology company that is developing and marketing Levulan((R)) Photodynamic Therapy (PDT) ... today its corporate highlights and financial results for the second quarter ... http://www.newscom.com/cgi-bin/prnh/20090810/D C 59366LOGO ) ...
... OF PRUSSIA, Pa., Aug. 11 At the CBI 3rd Annual ... announced the commercial release of CompleteSpend(TM) V2.5. CompleteSpend is the ... compliance needs. , , (Logo: ... , , Myriad state and pending federal laws ...
... Awarded $100,000 for Enhancing Health Care Delivery , , ... , , WASHINGTON , Aug. 11 Dr. ... his exceptional work to enhance health care delivery for hundreds of low income ... prize, named for Joseph H. Kanter, a pioneering advocate for electronic medical records, ...
... , , , , ... 2009 , PADRES Contra El Cancer (PADRES), a non-profit organization committed to improving ... the Spike for HOPE! Celebrity Volleyball match as part of the ... PRESENTED BY VIRGIN AMERICA . , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090811/LA59829 ...
Cached Medicine News:Health News:Middle-Aged Senior Care Advocate to Move Into D.C. Retirement Community 2Health News:BrainScope(TM) Receives FDA Clearance for Portable EEG Device 2Health News:BrainScope(TM) Receives FDA Clearance for Portable EEG Device 3Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 2Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 3Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 4Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 5Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 6Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 7Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 8Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 9Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 10Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 11Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 12Health News:DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 13Health News:Health Market Science Announces Commercial Release of CompleteSpend V2.5 2Health News:Health Market Science Announces Commercial Release of CompleteSpend V2.5 3Health News:Dr. James O'Connell Named J.H. Kanter Prize Laureate 2Health News:Dr. James O'Connell Named J.H. Kanter Prize Laureate 3Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 2Health News:Kevin Nealon, Jordan Farmar, Walter Perez, Cristian de la Fuente and Other Celebrities Participated in Beach Volleyball Match for Children With Cancer 3
... 8F Percutaneous Vascular Surgical (PVS) System consists of ... Perclose Knot Pusher. The Prostar XL 8F PVS ... two pairs of sutured needles as well as ... precisely control the needles during deployment. the Perclose ...
... The new solid-state IRIS Medical IQ ... the treatment of retinal disorders and ... represents its latest technological innovation and ... Minimum Intensity Photocoagulation (MIP) procedures in ...
... The AIA-360 is a sophisticated Aumated Immunoassay Analyzer ... analyzer has a footprint of 16 X 16 ... Its compact design is ideal for physician ... testing, such as cardiac panels, as well as ...
... Solitaire represents the latest in green laser ... for use in both the operating room ... preference testing and the most experienced ophthalmic ... is the premium 532nm photocoagulator - unique ...
Medicine Products: